Loading news...
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) was the target of a significant drop in short interest in February. As of February 13th, there was short interest totaling 4,262,939 shares, a drop of 20.9% from the January 29th total of 5,390,908 shares. Approximately 6.1% of the company's stock are sold short. Based on an
IO Biotech, Inc. (IOBT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totaling 3,083,794 shares, an increase of 47.2% from the December 31st total of 2,094,316 shares. Currently, 4.4% of the company's shares are sold short.
Raymond James engaged as financial advisor Reduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James & Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives. The company also announced that it is implementing cost-containment and cash conservation measures, including a significant reduction of the company's workforce, to reduce operating expenses while the company explores strategic alternatives.
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that the company intends to explore a range of strategic alternatives to maximize stockholder value. Strategic alternatives that may be evaluated include, but are not limited to, a merger, a business combination, a sale of assets or other strategic transaction or a liquidation and dissolution.
Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanoma Five-year analysis of median progression free survival was 25.5 months These results reinforce the potential of immune-modulatory vaccination NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the publication in Nature Communications of the long-term clinical and immunological outcomes from MM1636, the Phase 1/2 trial evaluating the investigational peptide vaccine IO102-IO103 targeting both tumor cells and immune-suppressive cells expressing IDO1 and/or PD-L1, in combination with PD-1 blockade in the treatment of first line metastatic melanoma. The results of this trial supported a Breakthrough Therapy Designation for the treatment of unresectable/metastatic melanoma in combination with pembrolizumab by the US Food and Drug Administration (FDA) and, together with the available preclinical and translational data, served as the foundation for IO Biotech's decision to initiate the Phase 3 clinical trial in first-line advanced melanoma (IOB-013/KN-D18).
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the Company's participation in the 8th Annual Evercore Healthcare Conference taking place in Florida on December 2, 2025, as well as the Piper Sandler Annual Healthcare Conference in New York on December 3, 2025. Mai-Britt Zocca, PhD, President & CEO, and Amy Sullivan, CFO, will participate in a fireside chat and host one-on-one meetings with investors at each conference.
IO Biotech, Inc. (IOBT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) has earned an average rating of "Hold" from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company.
Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, although statistical significance on the PFS primary endpoint was narrowly missed Meeting scheduled with FDA in December to align on the design of a potential new Phase 3 registrational trial for IO102-IO103 in patients with advanced melanoma Pre-clinical data for additional T-win platform pipeline candidates IO112 targeting arginase 1 and IO170 targeting transforming growth factor (TGF)-β were presented at the Society for Immunotherapy of Cancer's (SITC) Annual Meeting Ended the third quarter with approximately $31 million in cash and cash equivalents, which is expected to support operations through the first quarter of 2026 Corporate presentations planned for the Jefferies Global Healthcare Conference in London on November 18, 2025, and the Piper Sandler 37th Annual Piper Sandler Healthcare Conference on December 3, 2025 NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today reported financial results for the third quarter of 2025 and recent business highlights. “We remain keenly focused on our mission to develop novel, immune-modulatory, off-the-shelf cancer therapies for the treatment of multiple types of tumors including melanoma, lung, and head and neck cancer,” said Mai-Britt Zocca, PhD, President and CEO of IO Biotech.
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that members of its senior management team will participate in the following upcoming investor conferences: Event: Jefferies Global Healthcare ConferenceLocation: LondonPresentation: Tuesday, November 18, 2025, at 3:00 PM GMT Presenter: Mai-Britt Zocca, PhD, President & CEOWebcast Link: https://wsw.com/webcast/jeff332/iobt/1846538 Event: Piper Sandler 36th Annual Healthcare ConferenceLocation: New YorkFireside chat: Wednesday, December 3, 2025, at 3:00 pm ETPresenter: Mai-Britt Zocca, PhD, President & CEOWebcast Link: https://event.webcasts.com/starthere.jsp?ei=1742757&tp_key=8b79a34402 A webcast replay of the Jefferies corporate presentation and Piper fireside chat will be available on IO Biotech's website at www.iobiotech.com for 90 days following the presentation. About IO Biotech IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform.
Pre-clinical data for IO Biotech's next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted modulation of immunosuppressive myeloid cells, including tumor-associated macrophages (TAMs) Pre-clinical data for IO Biotech's additional T-win vaccine candidate, IO170 targeting Transforming Growth Factor (TGF)-β, demonstrates induction of immune responses that could inhibit tumor growth and reduce lung metastasis Data presented at the Society for Immunotherapy of Cancer's Annual Meeting NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced new pre-clinical data for IO Biotech's next vaccine candidate, IO112, and additional candidate, IO170, will be presented at the Society for Immunotherapy of Cancer's 40th Annual Meeting (SITC 2025) in Maryland on November 5-9, 2025. “This new data is extremely important for our development path as it points toward more potential indications for our novel, immune-modulatory therapeutic vaccines to treat patients with a range of cancers,” said Mai-Britt Zocca, PhD, President and CEO of IO Biotech.
Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS) primary endpoint for statistical significance Improvement in PFS favored the combination across virtually all subgroups, notably in patients with PD-L1-negative tumors, BRAF V600 -mutated tumors, and elevated LDH, without adding any systemic toxicity compared to pembrolizumab alone Final data from the Phase 2 basket trial in lung and head & neck cancers also presented NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today presented detailed results from its global Phase 3 trial (IOB-013/KN-D18) of Cylembio® (imsapepimut and etimupepimut, adjuvanted), in combination with Merck's (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab), for the first-line treatment of patients with unresectable or metastatic (advanced) melanoma. The data, presented as a proffered paper at the Melanoma and other skin tumors session of the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, expand upon topline results reported in August 2025.
FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical trial Company plans to design new registrational study for Cylembio for the treatment of first-line patients with advanced melanoma Company implementing a restructuring, reducing its workforce by approximately 50 percent NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today provided an update on the regulatory pathway for Cylembio® (imsapepimut and etimupepimut, adjuvanted) following a pre-BLA meeting with the U.S. Food and Drug Administration (FDA).
Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanoma Poster presentation will share final data from Phase 2 basket trial (IOB-022/KN-D38) of IO102-IO103 cancer vaccine plus pembrolizumab for 1L treatment of solid tumors NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announces a late-breaking abstract has been accepted and selected as a Proffered Paper oral presentation at the 2025 European Society for Medical Oncology (ESMO) Congress taking place in Berlin, Germany from October 17-21, 2025.
IO Biotech, Inc. (NASDAQ:IOBT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Company Participants Mai-Britt Zocca - Founder, President, CEO, Principal Financial Officer & Director Qasim Ahmad - Chief Medical Officer Amy Sullivan - Chief Financial Officer Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that members of its senior management team will provide a corporate update and participate in one-on-one meetings at the following upcoming investor conferences: Event: Morgan Stanley 23rd Annual Global Healthcare ConferenceLocation: New York, New YorkFireside Chat Date & Time: Tuesday, September 9, 2025 at 7:45 am ETPresenters: Mai-Britt Zocca, PhD, President and CEO, Amy Sullivan, CFO, and Qasim Ahmad, MD, CMOWebcast Link: Here Event: H.C.
IO Biotech, Inc. (IOBT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Announced clinical improvement in progression free survival observed in pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (pembrolizumab) for the treatment of first-line advanced melanoma, but statistical significance narrowly missed; company plans to meet with FDA this fall to discuss data and next steps for a potential regulatory submission Ended second quarter with approximately $28.1 million in cash and cash equivalents; the company expects that our cash position, together with €12.5 million in proceeds from the second tranche of the European Investment Bank (EIB) loan facility received on July 4, 2025, will be sufficient to continue funding our operations into the first quarter of 2026 Corporate presentations are planned for the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025 NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today reported financial results and business highlights for the second quarter of 2025.
IO Biotech's phase 3 melanoma trial showed a strong PFS benefit, especially in true 1st-line and PD1-negative patients, despite narrowly missing statistical significance. I believe the FDA should accept a submission based on these compelling, double-blind, randomized trial results, which show consistent benefits across subgroups. Key risks include potential FDA rejection, a dilutive cash raise, and limited US patient enrollment, but upcoming catalysts could strengthen IOBT's position.